Associations - ipatasertib (RG7440)

AKT1 mutation	Triple Negative Breast Cancer	AKT1 mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PTEN mutation	Triple Negative Breast Cancer	PTEN mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	RG7440 Resistant: B - Late Trials RG7440 Resistant : B	RG7440 Resistant: B - Late Trials RG7440 Resistant : B
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PTEN negative	Prostate Cancer	PTEN negative	Prostate Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PTEN-L	Triple Negative Breast Cancer	PTEN-L	Triple Negative Breast Cancer	RG7440 Sensitive: C2 – Inclusion Criteria RG7440 Sensitive : C2	RG7440 Sensitive: C2 – Inclusion Criteria RG7440 Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	RG7440 Sensitive: C2 – Inclusion Criteria RG7440 Sensitive : C2	RG7440 Sensitive: C2 – Inclusion Criteria RG7440 Sensitive : C2
PTEN mutation	Glioblastoma	PTEN mutation	Glioblastoma	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3
PTEN-L	Endometrial Cancer	PTEN-L	Endometrial Cancer	cobimetinib + RG7440 Sensitive: C3 – Early Trials cobimetinib + RG7440 Sensitive : C3	cobimetinib + RG7440 Sensitive: C3 – Early Trials cobimetinib + RG7440 Sensitive : C3
PTEN-L	Ovarian Cancer	PTEN-L	Ovarian Cancer	cobimetinib + RG7440 Sensitive: C3 – Early Trials cobimetinib + RG7440 Sensitive : C3	cobimetinib + RG7440 Sensitive: C3 – Early Trials cobimetinib + RG7440 Sensitive : C3
KRAS mutation	Endometrial Cancer	KRAS mutation	Endometrial Cancer	cobimetinib + RG7440 Sensitive: C3 – Early Trials cobimetinib + RG7440 Sensitive : C3	cobimetinib + RG7440 Sensitive: C3 – Early Trials cobimetinib + RG7440 Sensitive : C3
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	cobimetinib + RG7440 Sensitive: C3 – Early Trials cobimetinib + RG7440 Sensitive : C3	cobimetinib + RG7440 Sensitive: C3 – Early Trials cobimetinib + RG7440 Sensitive : C3
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3
PTEN mutation	Prostate Cancer	PTEN mutation	Prostate Cancer	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3
TP53 mutation	Prostate Cancer	TP53 mutation	Prostate Cancer	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3
FOXA mutation	Prostate Cancer	FOXA mutation	Prostate Cancer	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib + RG7440 Sensitive: C3 – Early Trials palbociclib + RG7440 Sensitive : C3	palbociclib + RG7440 Sensitive: C3 – Early Trials palbociclib + RG7440 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	RG7440 Sensitive: C3 – Early Trials RG7440 Sensitive : C3	RG7440 Sensitive: C3 – Early Trials RG7440 Sensitive : C3
AKT1 E17K	Breast Cancer	AKT1 E17K	Breast Cancer	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	atezolizumab + RG7440 Sensitive: C4 – Case Studies atezolizumab + RG7440 Sensitive : C4	atezolizumab + RG7440 Sensitive: C4 – Case Studies atezolizumab + RG7440 Sensitive : C4
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	dasatinib + RG7440 Sensitive: D – Preclinical dasatinib + RG7440 Sensitive : D	dasatinib + RG7440 Sensitive: D – Preclinical dasatinib + RG7440 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	sunitinib + RG7440 Sensitive: D – Preclinical sunitinib + RG7440 Sensitive : D	sunitinib + RG7440 Sensitive: D – Preclinical sunitinib + RG7440 Sensitive : D
KRAS mutation	Endometrial Cancer	KRAS mutation	Endometrial Cancer	RG7440 Sensitive: D – Preclinical RG7440 Sensitive : D	RG7440 Sensitive: D – Preclinical RG7440 Sensitive : D
PIK3CA mutation	Endometrial Cancer	PIK3CA mutation	Endometrial Cancer	RG7440 Sensitive: D – Preclinical RG7440 Sensitive : D	RG7440 Sensitive: D – Preclinical RG7440 Sensitive : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	RG7440 Sensitive: D – Preclinical RG7440 Sensitive : D	RG7440 Sensitive: D – Preclinical RG7440 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	RG7440 + A-1331852 Sensitive: D – Preclinical RG7440 + A-1331852 Sensitive : D	RG7440 + A-1331852 Sensitive: D – Preclinical RG7440 + A-1331852 Sensitive : D

ipatasertib (RG7440)

Associations
(27)

Associations
(27)

ipatasertib (RG7440)

Associations(27)

Associations(27)

Associations
(27)

Associations
(27)